Markets
Inhibrx Biosciences Stock Plunges 7% After Higher Borrowing Costs Widen Its Quarterly Loss
The cancer-treatment developer cut research spending, but its loan balance rose to $275 million from $100 million a year earlier.
Inhibrx Biosciences (INBX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The cancer-treatment developer cut research spending, but its loan balance rose to $275 million from $100 million a year earlier.
SEC Filings
Borrowing costs pushed the quarterly loss higher even as research spending fell, with more cancer-trial results expected in 2027.
SEC Filings
An investor presentation filed Monday shows INBRX-106 combined with pembrolizumab achieved an 80% confirmed response rate versus 33% for the checkpoint inhibitor alone.